Epileptics’ Hopes Ride On Zynerba Pharmaceuticals For New Treatment
Stage Two of the cannabidiol (CBD) gel for the treating patients with adult epilepsy has begun.
Zynerba Pharmaceuticals, a pharmaceutical company specializing within the growth of artificial treatments that are cannabinoid announced in the to begin That it had begun phase two clinical trials of its CBD gel ZYN002 august.
The gel happens to be developed to deal with epilepsy that is adult who experiencerefractory focal seizures.
Chairman and CEO of Zynerba, Armando Anido, reported in a news release that the dosing of this first clients within the STAR 1 trial that is clinical a significant milestone for the business. Continue reading “Epileptics’ Hopes Ride On Zynerba Pharmaceuticals For New Treatment”